Key information

Recruitment dates:

1 May, 2016 to 19 May, 2018
(Trial recruitment closed)

Trial phase:

phase III

Treatment stage:

primary treatment

Trial investigator:

Professor Jonathan Ledermann

University College London Hospital, NW1 2BU

Trial website:

Tags:

Javelin 100
Previously untreated
epithelial ovarian cancer
stage III
stage IV
recently diagnosed

Acronym:

JAVELIN OVARIAN 100

Clinical trial locations

Location list

Address:
London
NW1 2BU
Address:
Mount Vernon Hospital
Northwood
Middlesex
HA6 2RN
Address:
Sutton
Surrey
SM2 5PT
Address:
Addenbrooke's Hospital
Cambridge
CB2 0QQ
Address:
London
SE1 9RT
Address:
London
SW3 6JJ
Address:
London
W12 OHS
Address:
Manchester
M20 4BX

Please note that recruitment for this trial is now closed.

Introduction

This is a phase III trial looking at the efficacy and safety of a drug called avelumab in combination with and / or following carboplatin and paclitaxel based chemotherapy. It is for women who have just been diagnosed with ovarian cancer who haven't started treatment. 

About the trial

This trial is looking at whether the additional drug treatment of avelumab alongside platinum based chemotherapy improves progression free survival (the length of time during and after treatment that a woman lives with the disease but it does not get worse) in women with stage III / IV disease at diagnosis.

It is a three arm trial:

  • Carboplatin and paclitaxel – three weekly (with the option of weekly paclitaxel)
  • Carboplatin and paclitaxel – followed by avelumab two weekly
  • Carboplatin and paclitaxel – three weekly (with the option of weekly paclitaxel) with avelumab three weekly during treatment followed by two weekly as maintenance

Who can take part?

Women who are recently diagnosed with epithilial ovarian cancer and have not yet received any treatment.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.